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SObjectives: Cardiac functional deterioration in dilated cardiomyopathy (DCM) is known to be reversed by intra-
myocardial up-regulation of multiple cardioprotective factors, whereas a prostacyclin analog, ONO1301, has
been shown to paracrinally activate interstitial cells to release a variety of protective factors. We here hypothe-
sized that intramyocardial delivery of a slow-releasing form of ONO1301 (ONO1301SR)might activate regional
myocardium to up-regulate cardiotherapeutic factors, leading to regional and global functional recovery inDCM.
Methods and Results: ONO1301 elevated messenger RNA and protein level of hepatocyte growth factor, vas-
cular endothelial growth factor, and stromal-derived factor-1 of normal human dermal fibroblasts in a dose-
dependent manner in vitro. Intramyocardial delivery of ONO1301SR, which is ONO1301 mixed with polylactic
and glycolic acid polymer (PLGA), but not that of PLGA only, yielded significant global functional recovery in
a canine rapid pacing–induced DCM model, assessed by echocardiography and cardiac catheterization (n ¼ 5
each). Importantly, speckle-tracking echocardiography unveiled significant regional functional recovery in the
ONO1301-delivered territory, consistent to significantly increased vascular density, reduced interstitial collagen
accumulation, attenuated myocyte hypertrophy, and reversed mitochondrial structure in the corresponding area.
Conclusions: Intramyocardial delivery of ONO1301SR, which is a PLGA-coated slow-releasing form of
ONO1301, up-regulated multiple cardiotherapeutic factors in the injected territory, leading to region-specific
reverse left ventricular remodeling and consequently a global functional recovery in a rapid-pacing–induced ca-
nine DCM model, warranting a further preclinical study to optimize this novel drug-delivery system to treat
DCM. (J Thorac Cardiovasc Surg 2013;146:413-21)Dilated cardiomyopathy (DCM) is characterized by progres-
sive and severe deterioration of cardiac function, eventually
leading to advanced heart failure necessitating surgical inter-
ventions such as cardiac transplantation1 or mechanical assist
device implantation,2 despite maximum currently available
medical therapy including angiotensin-converting enzyme in-
hibitor3 or beta-blocker.4 Despite a variety of etiologies
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The Journal of Thoracic and Cahypertrophy of cardiomyocytes associatedwithmitochondrial
dysfunction, increased interstitialfibrosis, and limited regional
blood flow.5-7 Pathologic left ventricular (LV) remodeling is
reportedly reversed, at least in part, by cell transplantation
that intramyocardially up-regulates multiple cardiotherapeu-
tic cytokines in a constitutive manner.8,9 However, cell
therapy is limited in the clinical arena owing to availability
of cell processing center or ethical issues. Therefore,
synthetic reagents that yield similar cardiotherapeutic effects
to cell transplantation have been sought.
Prostacyclin is an endogenous factor released by
endothelial cells, activating endothelial cells, fibroblasts,
or smooth muscle cells in an autocrine and paracrine man-
ner to release multiple growth factors or cytokines, conse-
quently producing local and systemic anti-inflammatory,
antifibrotic, proangiogenic, and antithrombotic effects.
However, clinical use of synthetic prostacyclin or prostacy-
clin analogs, such as epoprostenol and beraprost, for
chronic diseases is hampered by its chemical instability10,11
and therefore the delivery method.
ONO1301 is a synthetic prostacyclin analog having
a unique structural feature to maintain chemical stability,rdiovascular Surgery c Volume 146, Number 2 413
Abbreviations and Acronyms
DCM ¼ dilated cardiomyopathy
Dd ¼ end-diastolic left ventricular
dimension
Ds ¼ end-systolic left ventricular
dimension
E ¼ early transmitral filling wave
E0 ¼ early diastolic velocity of the mitral
annulus
EF ¼ ejection fraction
EDWT ¼ end-diastolic wall thickness
ELISA ¼ enzyme-linked immunosorbent
assay
ESWT ¼ end-systolic wall thickness
HGF ¼ hepatocyte growth factor
LV ¼ left ventricular (ventricle)
mRNA ¼ messenger RNA
ONO1301SR ¼ slow releasing form of ONO1301
PCR ¼ polymerase chain reaction
PLGA ¼ polylactic and glycolic acid
polymer
SDF-1 ¼ stromal-derived factor-1
VEGF ¼ vascular endothelial growth factor
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ONO1301 reportedly activates fibroblasts to release multiple
factors such as hepatocyte growth factor (HGF) and vascular
endothelial growth factor (VEGF),13 both ofwhich are known
to be cardiotherapeutic.14,15 Nakamura and associates13
reported that direct intramyocardial injection of ONO1301
yielded cardiotherapeutic effects in amodel of acute myocar-
dial infarction in the mouse. On the other hand, Hirata and
colleagues16 reported that subcutaneous injection of
ONO1301 improves global cardiac function associated with
globally reduced fibrosis and increased capillaries in a ham-
ster DCMmodel. However, it remains unclear that intramyo-
cardial delivery of ONO1301 would produce therapeutic
effects on a model of DCM heart failure in a large animal.
We therefore hypothesized that intramyocardial injection
of ONO1301 might activate regional interstitial cells
including fibroblasts in the injected area to locally up-
regulate multiple therapeutic factors, leading to region-
specific functional recovery in DCM. Thus, we investigated
therapeutic effects of local administration of a slow-
releasing form of ONO1301 on regional cardiac function
of DCM heart by using the canine rapid-pacing induction
that is an established DCM model.17,18
METHODS
Animal Care
All studies were performed with the approval of the institutional
ethics committee in Osaka University Graduate School of Medicine. All414 The Journal of Thoracic and Cardiovascular Surganimals were treated in compliance with the ‘‘Principles of Laboratory An-
imal Care’’ (the National Society for Medical Research) and the ‘‘Guide for
theCare andUseofLaboratoryAnimals’’ (National Institutes ofHealth pub-
lication). Human dermal fibroblasts were treated in compliance with the
principles outlined in the Declaration of Helsinki. All procedures and anal-
ysis were carried out in a blindedmanner.We had full access to and take full
responsibility for the integrity of data and agree to themanuscript as written.
Culture of Human Dermal Fibroblasts With
ONO1301 Added
Human dermal fibroblast cell line (NHDF; CryoNHDF Neo, Lonza,
Switzerland) was cultured in fine bubble mixing culture (FGM-2 Bulletkit,
Lonza) containing 2% fetal bovine serum. ONO1301 (0.1-1.0 mmol/mL)
was added for 72 hours after serum-free culture for 24 hours.
Generation of a Slow-Releasing Form of ONO1301
A slow releasing form of ONO1301 (ONO1301SR; Ono Pharmaceuti-
cal Co Ltd, Osaka, Japan) was created by polymerization of ONO1301
with polylactic and glycolic acid polymer (PLGA) as described
previously.19 In brief, ONO1301 (5 mg) was mixed with 100 mg of
PLGA in 0.1% polyvinyl alcohol with an equal molar ratio of lactic
acid/glycolic acid. Releasing time of ONO1301SR in vitro was between
about 14 days to 25 days, as determined by measuring residual
ONO1301 in the pellets by liquid chromatography.
Generation of Canine DCM Model and
Intramyocardial ONO1301SR Injection
Beagles weighing 10 kg (Oriental Yeast Co Ltd, Tokyo, Japan) were en-
dotracheally intubated and supported by mechanical ventilation under gen-
eral anesthesia using intravenous sodium pentobarbitual (6 mg/kg) for
induction and inhaled sevoflurane (1%-2%) for subsequent maintenance.
We maintained the adequacy of anesthesia evaluated by giving the dogs
electrical stimuli every 30 minutes. This evaluation was performed during
each operation for each procedure. The heart was exposed via the left fifth
intercostal space, and 2 bipolar pacing leads (FINELINE II EZ STEROX;
Boston Scientific, Boston, Mass) were attached on the free wall of the right
ventricle, connected to a pulse generator (INSIGNIA I, Boston Scientific)
placed in subcutaneous pocket. The ventricle was continuously paced at
240 beats/min for 8 weeks.18
Four weeks after rapid pacing commenced, either ONO1301SR or
PLGA polymer only was injected with a 26-gauge needle at 5 points of lat-
eral wall of the LVat regular intervals (total 15 mg of ONO1301 or PLGA
polymer was injected, ONO1301SR group and control group, n ¼ 5 each).
Rapid pacing was temporally discontinued during the injection procedure,
and it was set back at 240 beats/min the day after each operation. Dogs kept
on rapid pacing for 8 weeks were humanely killed under general anesthesia
with an overdose of intravenous sodium pentobarbitual (18 mg/kg) to
achieve complete sedation followed by administration of potassium-
based solution intravenously to assure that they were completely dead.
The hearts were retrieved at 4 weeks after injection of either ONO1301SR
or PLGA only.We here defined lateral LVwall where ONO1301SRwas di-
rectly injected as the ‘‘target site’’ and the septal wall as the ‘‘remote site.’’
Conventional and Speckle-Tracking
Echocardiography and Cardiac Catheterization
Transthoracic echocardiography (Altida; ToshibaMedical SystemsCor-
poration, Tochigi, Japan) was performed under general anesthesia by 1%
sevoflurane inhalation. End-diastolic and end-systolic LV dimensions (Dd
and Ds, respectively) and end-systolic and end-diastolic wall thickness
(ESWT and EDWT, respectively) of the target site and remote site were
measured at mid-LV short axis view by conventional echocardiography.
LV ejection fraction (EF) was calculated with biplanar Simpson‘s ruleery c August 2013
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calculated by measuring peak Doppler velocities of early transmitral filling
wave (E) and the peak early diastolic velocity of the mitral annulus (E0).
Speckle-tracking echocardiography and an offline software (Altida Ex-
tend; Toshiba Medical Systems Corporation) were used to measure radial,
circumferential, transverse, and longitudinal strains to quantitatively assess
regional LV wall motion.20 Radial and circumferential strains were mea-
sured from the mid-LV short-axis view, whereas transverse and longitudi-
nal strains were from the apical 4-chamber view.
Cardiac catheterization was performed under general anesthesia using 1%
sevoflurane inhalation. A 3F micromanometer-tipped catheter (SPR-249;
Millar Instruments, Inc, Houston, Tex) was inserted through the LV apex to
measureheart rate,LVmaximal systolic pressure,maximal rate of theLVpres-
sure change evaluating systolic preload-dependent LV function, and time con-
stant of LV relaxation (t) evaluating diastolic load-dependent function.
Real-Time Polymerase Chain Reaction
Total RNAwas retrieved fromNHDFby usingRNeasyMini kit (Qiagen,
Venlo, The Netherlands) and treated with RNase-Free DNase Set (Qiagen).
TaqMan probes were designed using Primer Express software (Applied Bi-
osystems,Carlsbad,Calif). Real-time polymerase chain reaction (PCR)was
performed using a 7500 Fast Real-Time PCR Systemwith TaqManUniver-
sal PCRMaster Mix (Applied Biosystems). Concentration of HGF, VEGF,
and stromal-derived factor-1 (SDF-1) in the culture supernatant of NHDF
was measured by using an enzyme-linked immunosorbent assay (ELISA)
kit (Procarta Cytokine Assay kit, Panomics, Santa Clara, Calif).
Histologic Analysis and Electron Microscopy
The extracted dog hearts were transversely cut, fixed with 10% buffered
formalin, and embedded in paraffin. The heart sections of 10-mm thickness
were stained with hematoxylin and eosin, Masson-trichrome, picro-sirius
red, and periodic acid–Schiff. The heart sections were also labeled by
anti-von Willebrand factor antibody (Dako EPOS) visualized by horserad-
ish peroxidase (DakoCytomation, Glostrup, Denmark). Fibrotic area was
calculated in the picro-sirius red–stained sections by using a planimetric
method with a morphometry analyzer (NIS elements D, Nikon, Japan)
on 5 optical fields that were selected randomly for each sample. Extracted
dog heart tissues were fixed with 2.5% glutaraldehyde, stained with uranyl
acetate and lead citrate, and examined with a Hitachi H-7100 electron mi-
croscope (Hitachi High-Technologies, Tokyo, Japan).
Statistical Analysis
All data are presented as the mean  standard error of the mean. The
analyses were performed using nonparametric methods because the sample
sizes were too small to allow checking of the assumptions of parametric
methods. Expression of messenger RNA (mRNA) in vitro analyzed by
PCR and ELISA was analyzed by Jonckheere-Terpstra test for assuring
dose-dependent effect of ONO1301. Hemodynamic data obtained from
conventional echocardiography, cardiac catheterization, and speckle-
tracking echocardiography, as well as histopathologic findings such as per-
cent fibrosis, cell diameter, and vascular density at the target and remote
sites of control group or ONO1301SR group, were analyzed by nonpara-
metric repeated-measures analysis. Statistical analyses were performed
with the R program (R Development Core Team 2011). R: A language
and environment for statistical computing. R Foundation for Statistical
Computing; Vienna, Austria).RESULTS
Effects of ONO1301 on Expression of Endogenous
Cytokines In Vitro
Effects of ONO1301 on expression of HGF, VEGF, and
SDF-1 in the NHDF in vitro were examined by real-timeThe Journal of Thoracic and CaPCR and ELISA. Relative expression of mRNA for HGF,
VEGF, and SDF-1 was up-regulated in the NHDF with
ONO1301 added in a dose-dependent manner (Figure 1,
A-C), which was consistent with the release of HGF,
VEGF, and SDF-1 into the supernatants (Figure 1, D-F).
Global Recovery of the DCM Heart by Injection of
ONO1301SR
Serial changes in global systolic and diastolic cardiac
function were assessed under general anesthesia by conven-
tional echocardiography at 3 time points: 0 weeks (before
commencement of rapid pacing), 4 weeks after the com-
mencement of rapid pacing (just before injection of either
ONO1301SR or PLGA only), and 4 weeks after injection
of either ONO1301SR or PLGA only. Cardiac performance
was markedly deteriorated, including increased Dd/Ds and
E/E0 and decreased EF, ESWT, and EDWTat 4 weeks, when
either ONO1301MS or PLGA only was intramyocardially
injected.
At 4 weeks after PLGA injection, both systolic and dia-
stolic cardiac functions had further deteriorated.
On the other hand, EF and ESWT/ EDWTat both the tar-
get site and remote site at 4 weeks after ONO1301SR
injection were significantly greater than those at 4 weeks af-
ter PLGA injection (EF, 39%  1.7 % vs 19%  2.0%;
P< .05; Figure 2, E; ESWT/EDWT at target site, 1.3 
3.0 3 102 vs 1.1  2.0 3 102; P ¼ .01; Figure 2, C;
ESWT/EDWT at remote site, 1.2  0.1 vs 1.1 
3.0 3 102; P ¼ .04; Figure 2, D), although the impact of
the recovery was stronger in the target site. Ds was signifi-
cantly smaller after ONO1301SR injection than after PLGA
injection (Ds, 23  2.4 vs 31  1.7 mm; P<.05; Figure 2,
B), whereas Dd also showed a trend to be smaller after
ONO1301SR injection than after PLGA injection (Dd, 29
 2.3 vs 34  1.4; P < .05; Figure 2, A). E/E0 after
ONO1301SR injection was significantly smaller than that
after PLGA injection (E/E0, 11  1.2 vs 16  0.5;
P<.05; Figure 2, F).
Cardiac catheterization, carried out at 4 weeks after either
ONO1301SR or PLGA injection, revealed that t was signif-
icantly smaller after ONO1301SR injection than after PLGA
injection (t, 32  0.9 vs 55  5.8; P<.05). Heart rate, LV
maximal systolic pressure, and maximal rate of the LV
pressure change did not show any significant difference at
4 weeks after injection of either ONO1301SR or PLGA.
Regional Functional Recovery After ONO1301SR
Injection
Serial changes of regional systolic cardiac function
were assessed under general anesthesia by speckle-
tracking echocardiography at the same 3 time points as
conventional echocardiography. At 4 weeks after the com-
mencement of rapid pacing, all strain values at both target
and remote sites were decreased compared with thoserdiovascular Surgery c Volume 146, Number 2 415
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FIGURE 1. PCR and ELISA analysis in vitro showed that messenger RNA levels for HGF (A and D), VEGF (B and E), and SDF-1 (C and F) increased in
a dose-dependent manner in NHDF culturedwith ONO1301.PCR, Polymerase chain reaction;ELISA, enzyme-linked immunosorbent assay;NHDF, normal
human dermal fibroblast; HGF, hepatocyte growth factor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; SDF-1, stromal-derived factor-1; VEGF,
vascular endothelial growth factor. Mean  standard error of the mean, respectively.
Evolving Technology/Basic Science Shirasaka et al
E
T
/B
S before rapid pacing. At 4 weeks after the PLGA injection,
the absolute values of peak systolic radial, circumferential,
transverse, and longitudinal strains at both target and re-
mote sites further decreased compared with those before
the PLGA injection. In contrast, at 4 weeks after the
ONO1301SR injection, strain values of radial, transverse,
and circumferential strains were greater at the target
site than those after the PLGA injection (radial strain,
36%  4.7% vs 8.3%  1.4%; P<.05; transverse strain,
39%  9.3% vs 9.5%  2.1%; P<.05; circumferential
strain, 11%  1.3% vs 3.9%  0.6%; P < .05;
Figure 3, A-C), although longitudinal strain was not differ-
ent between the hearts with and without ONO1301SR
treatment (Figure 3, D). On the other hand, only radial
strain was significantly improved at the remote site after
ONO1301SR injection compared with that after PLGA
injection (Figure 3, E-H).
Histologic Findings of Reverse LV Remodeling After
ONO1301SR Injection
Gross myocardial structure, assessed by hematoxylin and
eosin staining and Masson trichrome staining, showed
a thicker LV wall and a smaller LV cavity 4 weeks after
ONO1301SR administration (Figure 4, H-K) than that after
PLGA injection (Figure 4, D-G).416 The Journal of Thoracic and Cardiovascular SurgQuantity of interstitial fibrosis at the target site, evaluated
by picro-sirius red staining, was significantly less at 4 weeks
after ONO1301SR administration compared with that after
PLGA injection (percent fibrosis at the target site, 9.9% 
0.7% vs 23%  0.9%; P< .01; Figure 4, A). Of note,
distribution of interstitial fibrosis was significantly more
restricted at the target site than that at the remote site
after ONO1301SR administration (9.9%  0.7% vs 16%
 1.2%), whereas PLGA injection did not produce such
an uneven distribution (23%  0.9% at the target site vs
23%  0.8% at the remote site).
Mean transverse cellular diameter of cardiomyocytes
(Figure 4, B) at the target site, measured by periodic acid-
Schiff–stained sections, was also significantly smaller at 4
weeks after ONO1301SR administration compared with
that after PLGA injection (12  0.6 mm vs 15  0.8 mm;
P< .01). The diameter of cardiomyocytes at the target
site was smaller after ONO1301SR administration com-
pared with that at the remote site (12  0.6 vs 14  0.3
mm; P<.01), whereas such an uneven distribution in the
myocyte size was not observed after PLGA injection.
Vascular density (Figure 4, C), assessed by counting the
number of factor VIII–positive cells in the fields, was signif-
icantly greater at the target site at 4 weeks after
ONO1301SR administration compared with that afterery c August 2013
FIGURE 2. Echocardiography (A-F) showed ONO1301SR significantly improved distressed cardiac function. Note that ESWT/EDWT, reflecting on the
radial strain of myocardium, was significantly more recovered in the ONO1301SR group than in the control group and that the clinical impact was more
prominent in the target site after ONO1301SR treatment. Dd, End-diastolic dimension of the left ventricle; Ds, end-systolic dimension of the left ventricle;
EF, ejection; ESWT, end-systolic wall thickness; EDWT, end-diastolic wall thickness. Mean  standard error of the mean, respectively. Ind, induction of
rapid pacing; Pre, before treatment of polylactic and glycolic acid polymer (PLGA) or ONO1301SR; Post, after treatment of PLGA or ONO1301SR.
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The vascular density at the target site was greater after
ONO1301SR administration compared with that at the re-
mote site (998  70/mm2 vs 491  24/mm2), whereas
such an uneven distribution of vascular density was not ob-
served after PLGA injection.
Electron microscopy revealed that the cardiomyocytes
at 4 weeks after PLGA injection showed a prominent
swelling or disruption of mitochondria, intracellular or
perinuclear edema, and sarcoplasmic vacuoles resulting
from dilation of sarcoplasmic reticulum (Figure 5, A).
However, marked loss of myofilaments and alterations of
characteristic sarcomeric structure were not observed in
any groups. Although the interfibrillar space in the myo-
cardium after ONO1301SR injection was slightly wid-
ened, the mitochondria were compact and showed
densely packed cristae (Figure 5, B) compared with those
after PLGA injection.The Journal of Thoracic and CaDISCUSSION
We here demonstrate that ONO1301 dose-dependently
up-regulated expression of multiple cytokines, such as
HGF, VEGF, and SDF-1, in fibroblasts in vitro. Histologic
reverse LV remodeling, such as attenuated fibrosis and
swelling of cardiomyocytes, increased vascular density,
and recovered mitochondrial structure, in the target area
but not significantly in the remote area, were consistent to
the regional functional recovery, assessed by speckle-
tracking echocardiography, which was more prominent at
the target area than that at the remote area after the
ONO1301SR injection. Such regional recovery at the target
area after ONO1301SR injection resulted in recovery of
global function, including systolic and diastolic function.
Iwata and associates21 reported that local administration
of prostacyclin analog may induce HGF production fol-
lowed by VEGF expression via cyclic adenosine mono-
phosphate–mediated pathway and that elevation of HGFrdiovascular Surgery c Volume 146, Number 2 417
FIGURE 3. Speckle-tracking echocardiography showed that the absolute values of peak radial, circumferential, and transverse strains at the target site in
the ONO1301SR group were significantly higher than in the control group (A-D) while all of them but radial strains at the remote site in the ONO1301SR
group and that in the control group were not significantly different (E-H), which implied that ONO1301SR had influence on the cardiac performance es-
pecially at the very site where ONO1301SR was administered; Radial, radial strain; Circumferential, circumferential strain; Transverse, transverse strain;
Longitudinal, longitudinal strain. Target site is defined as the area in which ONO1301SR or glycolic acid polymer (PLGA) is injected while remote site as
noninjection area. Ind, Induction of rapid pacing; Pre, before treatment of PLGA or ONO1301SR; Post, after treatment of PLGA or ONO1301SR. Mean
standard error of the mean, respectively.
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of ischemic heart failure. We here showed that ONO1301
directly activates fibroblasts in vitro and releases not only
HGF and VEGF, as reported previously,13,16,21 but also
SDF-1, which has been thought to be a representative ther-
apeutic stem cell homing factor in ischemic heart.22 In the
present in vivo study, we used the slow-releasing form to de-
liver ONO1301 and, importantly, deliver ONO1301SR di-
rectly into the myocardium of the canine DCM heart in
the aim to elevate regionally ONO1301 level, thus maxi-
mizing the effects on the cardiac fibroblasts to release car-
diotherapeutic factors. Consequently, pathologic and
functional effects of intramyocardial ONO1301SR injec-
tion were markedly prominent in the target area (area sur-
rounding the injection sites) compared with the remote
area, suggesting that cardiac fibroblasts residing in the tar-
get area might have played a key role in locally up-
regulated cardiotherapeutic cytokines.
In addition, it was noted that the typical structural fea-
tures of cardiomyocytes in the severely ischemic heart,418 The Journal of Thoracic and Cardiovascular Surgsuch as swelling of mitochondria, intracellular or perinu-
clear edema, and sarcoplasmic vacuoles referred to by a phe-
nomenon, ‘‘permeability transition,’’23 were reversed after
ONO1301SR injection in this study. On the basis of these
findings, targeted injection of ONO1301SR into the dam-
aged myocardial area might maximize therapeutic effects
of ONO1301 that up-regulates cardiotherapeutic cytokines
in a regional concentration-dependent manner.
Use of slow releasing form in administratingONO1301 di-
rectly into the heart includes concerns related to the initial
burst that might have an adverse effect on hemodynamics.24
In this study, there is no hemodynamic compromise during
or immediately after the procedure despite the poor cardiac
function, suggesting that the protocol used here in injecting
ONO1301SRmight be appropriate in treating theDCMheart.
Further study for dose-dependent hemodynamic change im-
mediately after ONO1301SR administration would be
needed in translating this treatment into the clinical arena.
Intramyocardial delivery of ONO1301 might be
achieved by direct injection, intracoronary artery injection,ery c August 2013
FIGURE 4. Histopathology; quantitative evaluation of interstitial fibrosis (A), mean cell diameter (B), vascular density (C), and representative micrograph
of the Control group (D-G) and the ONO1301SR group (H-K). D and H, Hematoxylin and eosin staining. E and I, Masson trichrome staining. F and J, Sirius
red staining. G and K, Staining with anti-human-von Willebrand factor. At the target site in the ONO1301SR group, the amounts of fibrosis and mean cell
diameter were significantly smaller and vascular density was significantly higher than those in the control group and those at the remote site in the
ONO1301SR group. Mean  standard error of the mean, respectively. LV, Left ventricle; RV, right ventricle.
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cific recovery, demonstrated in this study, would suggest
that direct injection of ONO1301 might be more effective
in the myocardium that has heterogeneous disease, such
as ischemic cardiomyopathy, as reported by Iwata and asso-
ciates.21 Combination with coronary artery bypass grafting
would also be a clinically applicable strategy for this pur-
pose. On the other hand, homogeneous disease such as
DCM might gain more therapeutic benefits by diffusely at-
taching ONO1301 on the epicardial surface compared with
direct injection, although further basic investigation will be
needed to establish this strategy. Intracoronary injection is
known to diffusely deliver reagents or cells into the myo-
cardium25; however, intracoronary injection of
ONO1301SR whose diameter is more than 20 mm will
cause coronary embolism and ischemic myocardial
damage.
This study is limited by the use of a canine model, which
is not exactly relevant to the clinical DCM diseases and hasThe Journal of Thoracic and Calimited reagents for mRNA or protein investigations
available.
However, a large animal model is essential in investigat-
ing cardiac performance by the latest technology used in
the clinical arena, such as speckle-tracking echocardiogra-
phy used in this study, whereas rodent models with or
without genetic modifications would be useful in
showing the mechanistic insights of this treatment. As
mechanistic insights have been reported by several studies,
the main focus of this study was to test the hypothesis
that intramyocardial injection of ONO1301 induces
region-specific and global functional recovery in dilated
cardiomyopathy. In addition, this study investigated the
mechanisms of this treatment to show the consistency
with the previous studies that used rodent models to prove
the mechanisms of this treatment.
Injection to the anterior wall and use of the posterior wall
as the control was an option; however, in the surgical view,
injection into the lateral wall produced consistent,rdiovascular Surgery c Volume 146, Number 2 419
FIGURE 5. Electron microscopy revealed that the myocardium of the control group (A) showed prominent swelling or disruption of mitochondria, intra-
cellular or perinuclear edema, and sarcoplasmic vacuoles resulting from dilation of sarcoplasmic reticulum (arrowhead). On the other hand, mitochondria in
the ONO1301SR group (B) were compact and showed densely packed cristae.
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the anterior wall. Therefore, injection of the reagent into
the lateral wall and septal wall was used as the control in
this study. However, pathophysiology of the septum are
substantially influenced by the performance of the RV.
In summary, we quantitatively evaluated region-specific
pathologic and functional effects of ONO1301SR, a slow-
releasing form of prostacyclin agonist, on a rapid-pacing ca-
nine DCM model. Multitherapeutic endogenous cytokines
induced by intramyocardial ONO1301SR injection may
be responsible for the improved cardiac performance and
ultrastructure. ONO1301SR is a promising therapeutic
drug for enhancing myocardial regeneration on the im-
paired myocardium.
We thankMasako Yokoyama, Yuka Fujiwara, and Shigeru Mat-
sumi for their excellent technical assistance.References
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